CASI Pharmaceuticals (CASIF) Asset Utilization Ratio (2024 - 2025)
CASI Pharmaceuticals (CASIF) reported Asset Utilization Ratio of 0.83 for Q4 2025, up 69.88% on a YoY basis from 0.49 in Q4 2024, and down 14.3% quarter-over-quarter from 0.96 in Q3 2025.
CASI Pharmaceuticals (CASIF) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.83 in Q4 2025.
- For the quarter ending Q4 2025, Asset Utilization Ratio rose 69.88% year-over-year to 0.83; the trailing twelve-month figure through Dec 2025 stood at 0.83 (up 69.88% YoY), and the FY2025 full-year result was 0.52, up 17.98% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.83, down from 0.96 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 2.02 in Q2 2025, with the low at 0.43 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | 0.55 |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | 0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.83 |
| Sep 30, 2025 | 0.96 |
| Jun 30, 2025 | 2.02 |
| Mar 31, 2025 | 1.17 |
| Dec 31, 2024 | 0.49 |
| Sep 30, 2024 | 0.69 |
| Jun 30, 2024 | 0.80 |
| Mar 31, 2024 | 0.43 |